DRREDDY - IntraDay Trade Analysis with Live Signals
← Back to ListKey Parameters
⭐ IntraDay Trade Rating: 3.2
✅ Positive
The stock is currently trading above its 50-day and 200-day moving averages, indicating positive momentum. Furthermore, the DII holding has increased significantly while FII holdings have decreased, suggesting growing domestic investor interest.
⚠️ Limitation
The RSI of 39.9 indicates that the stock may be undervalued but also suggests a potential lack of strong bullish momentum. The high PEG ratio (28.2) combined with the current price relative to its industry PE (147) suggests overvaluation.
📉 Company Negative News
Recent news highlights a significant purchase by Royal Bank of Canada, indicating positive sentiment, however, Qtr Profit Var (-86.3%) reflects a substantial decline in profits compared to the previous quarter.
📈 Company Positive News
The recent news indicates a substantial purchase of shares by Royal Bank of Canada, suggesting increased institutional interest and potentially driving further price appreciation.
🏭 Industry
The pharmaceutical sector is currently experiencing moderate growth driven by increasing healthcare expenditure and research & development investments, although profitability remains volatile due to patent expirations and generic competition.
🧾 Conclusion
A conservative entry point would be at 1175 ₹, utilizing the recent uptrend support. An initial profit-taking level could be set at 1200 ₹, targeting a 2.3% gain based on momentum. A stop-loss order should be placed at 1150 ₹ to mitigate potential downside risk given the RSI and high PEG ratio.